Schedule of Events

8:15-8:45 AM  Breakfast/Registration
8:50-9:00 AM  Opening Remarks
9:00-10:20 AM 1st Slide Session

Elizabeth Westgate
The Molecular Clock and Circadian Variability in Blood Pressure and Thrombosis

Steve Rudnick
Differential Effects of Secondary Structure on Antisense Oligonucleotide and Short Interfering RNA Mediated mRNA Cleavage

Eric Klein
The Role of Cellular Tension in G1-Phase Progression

Gene Ciccimaro
Probing the Interaction of Focal Adhesion Kinase and c-Src Using Mass Spectrometry

10:30-11:25 PM 1st Poster Session
11:30-12:30 PM Luncheon
12:30-1:30 PM 2nd Poster Session
1:40-3:00 PM 2nd Slide Session

Bisen Ding
Prophylactic thrombolysis in the pulmonary vasculature by PECAM-directed endothelial surface targeting of a PAI-1 resistant mutant pro-urokinase fusion construct that is activated and released by thrombin

Erin Griner
Generation of an I130A β2-chimaerin Knock-in Mouse to Study the Function of β2-chimaerin in vivo

David Kim
The Relative Role of DAF and Crry in Protecting Host Cells from Complement Attack

Elizabeth Schwarzbach
Defining the Mechanisms Contributing To Cognitive Impairment And Seizure Disorders Following Traumatic Brain Injury

3:00-4:00 PM  The John S. O’Brien Memorial Lecture:
Creating New Hope: Translating Genomics into Medicine

Dr. Peter S. Kim
President, Merck Research Laboratories

4:00-4:50 PM  Cheese and wine
The John S. O’Brien Memorial Lecture in Pharmacology

“Creating New Hope: Translating Genomics into Medicine”

Peter S. Kim, Ph.D.
President,
Merck Research Laboratories

Peter S. Kim, Ph.D., 48, is a structural biologist known for discovering how proteins cause membranes to fuse, a central feature of all life. He has designed novel compounds that stop membrane fusion by the AIDS virus, thereby preventing it from infecting cells.

Dr. Kim was appointed president of Merck & Co.’s Merck Research Laboratories (MRL) on January 1, 2003, and he is responsible for all of Merck’s drug and vaccine discovery and development activities. Previously, Dr. Kim served as MRL’s executive vice president of Research and Development from February 1, 2001 to December 31, 2002.

Prior to joining Merck, Dr. Kim was a Professor of Biology at Massachusetts Institute of Technology (MIT). He was also a Member of the Whitehead Institute and an Investigator at the Howard Hughes Medical Institute. Dr. Kim also served as a member of the National Institutes of Health (NIH) Advisory Committee to develop an AIDS vaccine.

Dr. Kim received his undergraduate education at Cornell University, graduating with distinction in chemistry. He received his Ph.D. in biochemistry from Stanford University in 1985. While at Stanford, he was also a Medical Scientist Training Program Fellow.

His work has earned him numerous awards including the National Academy of Sciences Award in Molecular Biology, the Eli Lilly Award in Biological Chemistry, the Hans Neurath Award of the Protein Society, and the Samsung Foundation Ho-Am Prize in Basic Science. Dr. Kim was elected a member of the National Academy of Sciences in 1997 and is also a member of its Institute of Medicine.

Dr. Kim currently is a member of the Board of Directors at Fox Chase Cancer Center and at the Whitehead Institute for Biomedical Research. He is a member of the Oversight Committee, Division on Earth and Life Studies of the National Academies and a member of the Council of the Institute of Medicine.